Clinical value of magnetic resonance spectroscopy in assessment of early curing impact of concurrent chemoradiotherapy after high-grade glioma surgery
Background/Aim. High-grade glioma (HGG) is an interstitial cell-derived primary tumor of the nervous system. The current guidelines for the diagnosis and treatment of glioma recommend the maximum safe range of tumor resection for treatment methods. Adjuvant concurrent chemoradiotherapy is recommende...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
2024-01-01
|
| Series: | Vojnosanitetski Pregled |
| Subjects: | |
| Online Access: | https://doiserbia.nb.rs/img/doi/0042-8450/2024/0042-84502400041G.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849471731286147072 |
|---|---|
| author | Gao Yu Yan Wen-Ming Wang Hong-Wei Li Xin-Hong Zhang Ru-Tao Dong Yu-Bo Zhang Wei-Han Guo Qi-Wei |
| author_facet | Gao Yu Yan Wen-Ming Wang Hong-Wei Li Xin-Hong Zhang Ru-Tao Dong Yu-Bo Zhang Wei-Han Guo Qi-Wei |
| author_sort | Gao Yu |
| collection | DOAJ |
| description | Background/Aim. High-grade glioma (HGG) is an interstitial cell-derived primary tumor of the nervous system. The current guidelines for the diagnosis and treatment of glioma recommend the maximum safe range of tumor resection for treatment methods. Adjuvant concurrent chemoradiotherapy is recommended after surgery, followed by six cycles of single-drug chemotherapy, temozolomide. Evaluation of the early efficacy of concurrent chemoradio-therapy after HGG surgery, especially for patients with a high risk of recurrence, is a crucial step in enhancing the treatment efficiency for patients diagnosed with HGG. In this study, we investigated the clinical utility of magnetic resonance (MR) spectroscopy (MRS) in assessing the early curing impact of concurrent chemoradiotherapy following HGG surgery. Methods. A total of 50 patients with incomplete resection or suspected residual postoperative HGG, treated in the radiotherapy department of our hospital between January 2016 and June 2021, were selected for routine concurrent chemoradiotherapy. Conventional MR imaging and MRS were performed one week prior to treatment and one month after treatment to assess changes in specific brain metabolites. All 50 patients were followed up for 6 to 12 months. Based on the follow-up results, the patients were divided into two groups: the tumor recurrence group and the tumor suppression group. One month after the end of the treatment, the differences in levels of brain metabolites between the two groups were analyzed using MRS. Results. The levels of N-acetylaspartate (NAA) and creatine (Cr) increased after radiotherapy, while choline (Cho) peak value, and Cho/Cr, NAA/Cr, and Cho/NAA ratios decreased compared to pre-treatment levels. There were statistically significant differences in the NAA peak value, and Cho/Cr, and Cho/NAA ratios in the tumor enhancement area before and after treatment (p < 0.05). There were also statistically significant differences in Cho/Cr ratio in the peritumoral edema area before and after treatment (p < 0.05). Conclusion. After concurrent chemoradiotherapy, MRS can be used to detect early metabolic changes in the tumor enhancement and peritumoral edema areas of HGG. |
| format | Article |
| id | doaj-art-bf05624566d84846a2ecd3f53ab47ff2 |
| institution | Kabale University |
| issn | 0042-8450 2406-0720 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade |
| record_format | Article |
| series | Vojnosanitetski Pregled |
| spelling | doaj-art-bf05624566d84846a2ecd3f53ab47ff22025-08-20T03:24:44ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502406-07202024-01-0181740741310.2298/VSP240109041G0042-84502400041GClinical value of magnetic resonance spectroscopy in assessment of early curing impact of concurrent chemoradiotherapy after high-grade glioma surgeryGao Yu0Yan Wen-Ming1Wang Hong-Wei2Li Xin-Hong3Zhang Ru-Tao4Dong Yu-Bo5Zhang Wei-Han6Guo Qi-Wei7The Affiliated Hospital of Inner Mongolia Medical University, Department of Radiotherapy, Hohhot, ChinaThe Affiliated Hospital of Inner Mongolia Medical University, Department of Radiotherapy, Hohhot, ChinaThe Affiliated Hospital of Inner Mongolia Medical University, Department of Radiotherapy, Hohhot, ChinaThe Affiliated Hospital of Inner Mongolia Medical University, Department of Radiotherapy, Hohhot, ChinaThe Affiliated Hospital of Inner Mongolia Medical University, Department of Radiotherapy, Hohhot, ChinaThe Affiliated Hospital of Inner Mongolia Medical University, Department of Radiotherapy, Hohhot, ChinaThe Affiliated Hospital of Inner Mongolia Medical University, Department of Radiotherapy, Hohhot, ChinaTogtoh County Hospital, Department of Radiotherapy, Hohhot, ChinaBackground/Aim. High-grade glioma (HGG) is an interstitial cell-derived primary tumor of the nervous system. The current guidelines for the diagnosis and treatment of glioma recommend the maximum safe range of tumor resection for treatment methods. Adjuvant concurrent chemoradiotherapy is recommended after surgery, followed by six cycles of single-drug chemotherapy, temozolomide. Evaluation of the early efficacy of concurrent chemoradio-therapy after HGG surgery, especially for patients with a high risk of recurrence, is a crucial step in enhancing the treatment efficiency for patients diagnosed with HGG. In this study, we investigated the clinical utility of magnetic resonance (MR) spectroscopy (MRS) in assessing the early curing impact of concurrent chemoradiotherapy following HGG surgery. Methods. A total of 50 patients with incomplete resection or suspected residual postoperative HGG, treated in the radiotherapy department of our hospital between January 2016 and June 2021, were selected for routine concurrent chemoradiotherapy. Conventional MR imaging and MRS were performed one week prior to treatment and one month after treatment to assess changes in specific brain metabolites. All 50 patients were followed up for 6 to 12 months. Based on the follow-up results, the patients were divided into two groups: the tumor recurrence group and the tumor suppression group. One month after the end of the treatment, the differences in levels of brain metabolites between the two groups were analyzed using MRS. Results. The levels of N-acetylaspartate (NAA) and creatine (Cr) increased after radiotherapy, while choline (Cho) peak value, and Cho/Cr, NAA/Cr, and Cho/NAA ratios decreased compared to pre-treatment levels. There were statistically significant differences in the NAA peak value, and Cho/Cr, and Cho/NAA ratios in the tumor enhancement area before and after treatment (p < 0.05). There were also statistically significant differences in Cho/Cr ratio in the peritumoral edema area before and after treatment (p < 0.05). Conclusion. After concurrent chemoradiotherapy, MRS can be used to detect early metabolic changes in the tumor enhancement and peritumoral edema areas of HGG.https://doiserbia.nb.rs/img/doi/0042-8450/2024/0042-84502400041G.pdfbiomarkerschemoradiotherapychemotherapyadjuvantgliomamagnetic resonance spectroscopyprognosissurgery |
| spellingShingle | Gao Yu Yan Wen-Ming Wang Hong-Wei Li Xin-Hong Zhang Ru-Tao Dong Yu-Bo Zhang Wei-Han Guo Qi-Wei Clinical value of magnetic resonance spectroscopy in assessment of early curing impact of concurrent chemoradiotherapy after high-grade glioma surgery Vojnosanitetski Pregled biomarkers chemoradiotherapy chemotherapy adjuvant glioma magnetic resonance spectroscopy prognosis surgery |
| title | Clinical value of magnetic resonance spectroscopy in assessment of early curing impact of concurrent chemoradiotherapy after high-grade glioma surgery |
| title_full | Clinical value of magnetic resonance spectroscopy in assessment of early curing impact of concurrent chemoradiotherapy after high-grade glioma surgery |
| title_fullStr | Clinical value of magnetic resonance spectroscopy in assessment of early curing impact of concurrent chemoradiotherapy after high-grade glioma surgery |
| title_full_unstemmed | Clinical value of magnetic resonance spectroscopy in assessment of early curing impact of concurrent chemoradiotherapy after high-grade glioma surgery |
| title_short | Clinical value of magnetic resonance spectroscopy in assessment of early curing impact of concurrent chemoradiotherapy after high-grade glioma surgery |
| title_sort | clinical value of magnetic resonance spectroscopy in assessment of early curing impact of concurrent chemoradiotherapy after high grade glioma surgery |
| topic | biomarkers chemoradiotherapy chemotherapy adjuvant glioma magnetic resonance spectroscopy prognosis surgery |
| url | https://doiserbia.nb.rs/img/doi/0042-8450/2024/0042-84502400041G.pdf |
| work_keys_str_mv | AT gaoyu clinicalvalueofmagneticresonancespectroscopyinassessmentofearlycuringimpactofconcurrentchemoradiotherapyafterhighgradegliomasurgery AT yanwenming clinicalvalueofmagneticresonancespectroscopyinassessmentofearlycuringimpactofconcurrentchemoradiotherapyafterhighgradegliomasurgery AT wanghongwei clinicalvalueofmagneticresonancespectroscopyinassessmentofearlycuringimpactofconcurrentchemoradiotherapyafterhighgradegliomasurgery AT lixinhong clinicalvalueofmagneticresonancespectroscopyinassessmentofearlycuringimpactofconcurrentchemoradiotherapyafterhighgradegliomasurgery AT zhangrutao clinicalvalueofmagneticresonancespectroscopyinassessmentofearlycuringimpactofconcurrentchemoradiotherapyafterhighgradegliomasurgery AT dongyubo clinicalvalueofmagneticresonancespectroscopyinassessmentofearlycuringimpactofconcurrentchemoradiotherapyafterhighgradegliomasurgery AT zhangweihan clinicalvalueofmagneticresonancespectroscopyinassessmentofearlycuringimpactofconcurrentchemoradiotherapyafterhighgradegliomasurgery AT guoqiwei clinicalvalueofmagneticresonancespectroscopyinassessmentofearlycuringimpactofconcurrentchemoradiotherapyafterhighgradegliomasurgery |